Call Option Price. The parties hereto stipulate that the price for the Call Option payable by GRANTEE to GRANTOR (the “Call Option Price”) shall be determined in EUR as follows: EUR 1,00.
Call Option Price. Call Option Price" means the purchase price payable upon SGH's exercise of the Call Option as set forth on the attached Schedule 3.8(B).
Call Option Price. In the event the Company exercises its Call Option, the exercise price shall be $1.63 per share (the “Call Option Price”).
Call Option Price. If HLL exercises the Call Option with respect to any MOA, HLL or its designee shall (i) unless the Call Option Triggering Event is an Event of SFL Default, pay to Holdings an amount equal to all out-of-pocket costs and expenses incurred by Holdings in connection with the subject MOA and/or the financing of the Vessel covered thereby which have not been previously paid or reimbursed by HLL, and (ii) cause the return of the deposit provided by Holdings (whether in the form of cash or a letter of credit and including any interest earned on such cash deposit) as a condition to Holdings making such assignment.
Call Option Price. The “Call Option Price” is equal to the outstanding principal amount of the Note, together with accrued and unpaid interest thereon, at the time Buyer delivers the Call Option Notice.
Call Option Price. (a) Within 10 Business Days following receipt of the Exercise Notice in respect of its Call Option Shares, the relevant Minority Investor shall notify Ingredion and the Company in writing whether:
(i) it accepts the Ingredion Call Option Price; or
(ii) whether it is immediately referring the determination of the fair value of the Call Option Shares to the Expert for determination in accordance with Schedule 4, and if the relevant Minority Investor does not give such notice within such time period, it is deemed that the relevant Minority Investor has accepted the Ingredion Call Option Price.
(b) For the purposes of this Agreement the "Call Option Price" applicable to the sale of the relevant Minority Investor's Call Option Shares shall be:
(i) the Ingredion Call Option Price if it is accepted, or deemed to be accepted, by the relevant Minority Investor in accordance with clause 22.4(a)(i); or
(ii) the Call Option Fair Price if the relevant Minority Investor has referred, in accordance with clause 22.4(a)(ii), determination of the Fair Price of the Call Option Shares to the Expert. Where more than one Minority Investor so refers at the same time or within a short period of another referral, then the Expert shall make a single determination of the Fair Value. For the avoidance of doubt, if the Call Option Fair Price is lower than the Ingredion Call Option Price then such lower price shall be the applicable Call Option Price.
Call Option Price. In connection with any exercise of the Call ----------------- Option, the purchase price for each Unvested Share for the Executive as to which a Termination has occurred (whether or not then held by that Executive) will be $0.001, and the purchase price for each other Executive Share for that Executive (whether or not then held by that Executive) will be the Fair Market Value of that Executive Share as of the date upon which the Company Call Notice or the Fund Call Notice, as the case may be, is given. The Fair Market Value of any Executive Share will be determined pursuant to Article 4.
Call Option Price. For purposes of this Clause 7.6:
(a) The Call Option Price for the Unrestricted Call Option Shares means the highest of:
(i) the value of the Technical Assistance and Technology Transfer Agreement for the Project, calculated as the sum of future Management Fees equal to 5% of GCN EBITDA as per Schedule I attached hereto, discounted at a rate of 10.75% plus the value of SETA's interest in GCN based on GCN equity valued at the price per share in U.S. Dollars payable in connection with the exercise of the 36% Option (less dividends paid by GCN from the date of exercise of the 36% Option up to an amount of US$140 million) pursuant to Section 3.4.1 of the Participation Agreement, indexed at a rate per annum equal to 5%, minus the Net Debt of SETA and
(ii) the average between (x) the value of the Technical Assistance and Technology Transfer Agreement, calculated as described in (i) above, plus the value of SETA's interest in GCN equity based on the basis of the most recent twelve months EBITDA of GCN multiplied by 9 times (minus GCN Net Debt), minus the Net Debt of SETA, and (y) the valuation provided by an internationally recognized investment bank through the delivery of a fairness opinion (such investment bank to be chosen by AEROINVEST out of two investment banks proposed by ADP, with the costs incurred in connection with the engagement of such investment bank to be borne equally by AEROINVEST and ADP).
(b) The Call Option Price per Restricted Call Option Share, if sold together with the Unrestricted Call Option Shares, shall be the same price per Unrestricted Call Option Share calculated in accordance with paragraph (a) above.
(c) The Call Option Price per Restricted Call Option Share, if not sold together with the Unrestricted Call Option Shares, shall be the same price per Unrestricted Call Option Share calculated in accordance with paragraph (a) above, indexed at a rate per annum equal to 5% from the date of payment of the Call Option Price for the Unrestricted Call Option Shares until the date of payment of the Call Option Price for the Restricted Call Option Shares.
(d) The Call Option Price for the ADP Call Option Shareholder Loans shall be the outstanding principal amount of such ADP Call Option Shareholder Loans plus any accrued but unpaid interest up to and including the date of payment of such Call Option Price.
(e) The Call Option Price per Unrestricted Call Option Share and per Restricted Call Option Share shall be adjusted to take into account ...
Call Option Price. 19.1 The purchase price payable by the Purchasers to the Grantee for the sale and transfer of each Option Share under the Call Option, shall be an amount equal to the aggregate of –
19.1.1 the Option Price Balance in respect of that Option Share as at the Call Option Closing Date; and
19.1.2 the Escalation Amount calculated in respect of that Option Share up to but excluding the Call Option Closing Date (which has not yet been compounded in terms of the provisions of clause 2.1.20.4 and included in the calculation of the Option Price Balance in terms of the provisions of clause 2.1.39.3).
19.2 The Grantee shall no less than 2 business days before the Call Option Closing Date, deliver written confirmation specifying the Call Option Price payable in respect of the Option Shares (which shall be determined in accordance with this clause 19).
19.3 The Call Option Price as set out in the written confirmation in terms of clause 19.2 signed by the Grantee or any director or manager of the Grantee (whose appointment need not be proved) as to the Call Option Price or the calculation of the Call Option Price, shall, in the absence of manifest error, be prima facie proof of the Call Option Price and the Grantee and the Purchasers will proceed to closing and implement the Sale on the Call Option Closing Date on the basis of the Grantee's calculations set out in the written confirmation in terms of clause 19.2.
Call Option Price. (a) Within 10 Business Days following receipt of the Exercise Notice in respect of its Call Option Shares, the relevant Minority Investor shall notify Ingredion and the Company in writing whether:
(i) it accepts the Ingredion Call Option Price; or
(ii) whether it is immediately referring the determination of the fair value of the Call Option Shares to the Expert for determination in accordance with Schedule 4, and if the relevant Minority Investor does not give such notice within such time period, it is deemed that the relevant Minority Investor has accepted the Ingredion Call Option Price.
(b) For the purposes of this Agreement the "Call Option Price" applicable to the sale of the relevant Minority Investor's Call Option Shares shall be:
(i) the Ingredion Call Option Price if it is accepted, or deemed to be accepted, by the relevant Minority Investor in accordance with clause 22.4(a)(i); or
